Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Is this the year?

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Jun 11, 2021 4:47pm

199 Views

Post# 33374052

RE:RE:RE:RE:RE:RE:Is this the year?

"My understanding is that the FDA wants to see the CR results of 20-25 patient at 360 days post initial treatment. "

When this statement says "360 days post initial treatment" is it referring to 360 days beyond Patient One's treatment being the 'initial treatment' or 360 days beyond Patient Twenty-Five's treatment with the term "initial" being all encomposing for the group of 25 as opposed to the singular first treatment? i.e. a play with words.

<< Previous

Bullboard Posts

Next >>

Mid-year review: How has gold been performing?